Pharmacologic Interventions for Painful Diabetic Neuropathy An Umbrella Systematic Review and Comparative Effectiveness Network Meta-analysis

被引:113
作者
Griebeler, Marcio L.
Morey-Vargas, Oscar L.
Brito, Juan P.
Tsapas, Apostolos
Wang, Zhen
Leon, Barbara G. Carranza
Phung, Olivia J. [1 ,2 ]
Montori, Victor M.
Murad, M. Hassan
机构
[1] Western Univ Hlth Sci, Coll Pharm, Pomona 91766, CA USA
[2] Western Univ Hlth Sci, Western Diabet Inst, Pomona, CA 91766 USA
关键词
ALDOSE-REDUCTASE INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED-RELEASE OXYCODONE; DOUBLE-BLIND; PERIPHERAL NEUROPATHY; SYMPTOMATIC TREATMENT; IMIPRAMINE TREATMENT; MULTICENTER TRIAL; TOPICAL CAPSAICIN; SODIUM VALPROATE;
D O I
10.7326/M14-0511
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple treatments for painful diabetic peripheral neuropathy are available. Purpose: To evaluate the comparative effectiveness of oral and topical analgesics for diabetic neuropathy. Data Sources: Multiple electronic databases between January 2007 and April 2014, without language restriction. Study Selection: Parallel or crossover randomized, controlled trials that evaluated pharmacologic treatments for adults with painful diabetic peripheral neuropathy. Data Extraction: Duplicate extraction of study data and assessment of risk of bias. Data Synthesis: 65 randomized, controlled trials involving 12 632 patients evaluated 27 pharmacologic interventions. Approximately one half of these studies had high or unclear risk of bias. Nine head-to-head trials showed greater pain reduction associated with serotonin-norepinephrine reuptake inhibitors (SNRIs) than anticonvulsants (standardized mean difference [SMD], -0.34 [95% credible interval {CrI}, -0.63 to -0.05]) and with tricyclic antidepressants (TCAs) than topical capsaicin 0.075%. Network meta-analysis showed that SNRIs (SMD, -1.36 [CrI, -1.77 to -0.95]), topical capsaicin (SMD, -0.91 [CrI, -1.18 to -0.08]), TCAs (SMD, -0.78 [CrI, -1.24 to -0.33]), and anticonvulsants (SMD, -0.67 [CrI, -0.97 to -0.37]) were better than placebo for short-term pain control. Specifically, carbamazepine (SMD, -1.57 [CrI, -2.83 to -0.31]), venlafaxine (SMD, -1.53 [CrI, -2.41 to -0.65]), duloxetine (SMD, -1.33 [CrI, -1.82 to -0.86]), and amitriptyline (SMD, -0.72 [CrI, -1.35 to -0.08]) were more effective than placebo. Adverse effects included somnolence and dizziness with TCAs, SNRIs, and anticonvulsants; xerostomia with TCAs; and peripheral edema and burning sensation with pregabalin and capsaicin. Limitation: Confidence in findings was limited because most evidence came from indirect comparisons of trials with short (-3 months) follow-up and unclear or high risk of bias. Conclusion: Several medications may be effective for short-term management of painful diabetic neuropathy, although their comparative effectiveness is unclear.
引用
收藏
页码:639 / U138
页数:12
相关论文
共 86 条
  • [1] EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
    Attal, N.
    Cruccu, G.
    Baron, R.
    Haanpaa, M.
    Hansson, P.
    Jensen, T. S.
    Nurmikko, T.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (09) : 1113 - E88
  • [2] Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial
    Backonja, M
    Beydoun, A
    Edwards, KR
    Schwartz, SL
    Fonseca, V
    Hes, M
    LaMoreaux, L
    Garofalo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21): : 1831 - 1836
  • [3] Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
    Bansal, D.
    Bhansali, A.
    Hota, D.
    Chakrabarti, A.
    Dutta, P.
    [J]. DIABETIC MEDICINE, 2009, 26 (10) : 1019 - 1026
  • [4] Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study
    Beydoun, A
    Shaibani, A
    Hopwood, M
    Wan, Y
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (06): : 395 - 404
  • [5] BIESBROECK R, 1995, ADV THER, V12, P111
  • [6] Diabetic neuropathies - A statement by the American Diabetes Association
    Boulton, AJM
    Vinik, AI
    Arezzo, JC
    Bril, V
    Feldman, EL
    Freeman, R
    Malik, RA
    Maser, RE
    Sosenko, JM
    Ziegler, D
    [J]. DIABETES CARE, 2005, 28 (04) : 956 - 962
  • [7] Pharmacologic management of painful diabetic neuropathy
    Andrew J. M. Boulton
    [J]. Current Diabetes Reports, 2008, 8 (6) : 429 - 430
  • [8] Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain
    Boyle, Julia
    Eriksson, Malin E. V.
    Gribble, Laura
    Gouni, Ravi
    Johnsen, Sigurd
    Coppini, David V.
    Kerr, David
    [J]. DIABETES CARE, 2012, 35 (12) : 2451 - 2458
  • [9] Bril V, 2011, PM&R, V3, P345, DOI [10.1016/j.pmrj.2011.03.008, 10.1212/WNL.0b013e3182166ebe]
  • [10] Diabetic neuropathy: clinical manifestations and current treatments
    Callaghan, Brian C.
    Cheng, Hsinlin T.
    Stables, Catherine L.
    Smith, Andrea L.
    Feldman, Eva L.
    [J]. LANCET NEUROLOGY, 2012, 11 (06) : 521 - 534